IN8bio (INAB) TD Cowen 45th Annual Healthcare Conference summary

Key announcements and new programs

• Announced a new program expanding gamma-delta T cell technology into autoimmune disease, in addition to ongoing cancer focus.

• Unveiled first data for INB-600, a gamma-delta T cell engager platform, and introduced INB-619 targeting CD19.

• Highlighted a unique B cell depleting T cell engager with potential for both oncology and autoimmune indications.

• Emphasized the ability to drive potent B cell depletion without lymphodepletion or associated toxicities.

• Announced plans to present additional scientific data at medical meetings in the spring and provide further clinical updates later in the year.

Clinical trial results and data highlights

• Reported durable remissions beyond three years in patients with glioblastoma and acute myeloid leukemia (AML).

• INB-100 trial in AML showed no relapses within one year and all patients alive at that mark, outperforming historical controls.

• INB-200 in glioblastoma demonstrated extended progression-free survival (12.4 months for multi-dose cohort), surpassing standard of care and recent comparators.

• No observed cytokine release syndrome or neurotoxicities in clinical trials, even with direct brain delivery.

• Ongoing expansion cohorts and plans to add more centers and a prospective control arm in AML trial.

Platform and technology insights

• Gamma-delta T cells described as "Nature's CAR-T," with ability to discriminate between healthy and tumor cells.

• T cell engager platform can expand both V delta 1 and V delta 2 compartments, offering advantages over CD3-based engagers.

• Platform enables potent B cell depletion at low effector-to-target ratios and in picomolar range.

• Avoids need for lymphodepletion, reducing risk of ovarian damage and other toxicities.

• Manufacturing is simpler and cheaper compared to cell therapies.